Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145480 · ClinicalTrials.gov registry record · Phase 2
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
A Phase 2 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03145480 is a Phase 2 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 3 participants.
The verdict
NCT03145480, a Phase 2 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research study studies the combination of ibrutinib and obinutuzumab with or without the standard chemotherapy regimen of CHOP to see how well these drugs work in treating patients with a diagnosis of Richter's Transformation or Richter's Syndrome. The Bruton's Tyrosine Kinase (BTK) inhibitor, ibrutinib, may stop growth of cancer cells by blocking the signal needed for cell growth. The monoclonal antibody obinutuzumab may block cancer growth by targeting cells present in Richter's Transformation. Giving ibrutinib with obinutuzumab may be a better treatment for patients with Richter's Transformation. Depending on fitness, the patients may receive ibrutinib and obinutuzumab in combination with a regimen known as CHOP (C= cyclophosphamide, H= hydroxydaunorubicin (also called doxorubicin), O= oncovin (also called vincristine, and P= prednisolone or prednisone (corticosteroids).
Interventions
- DRUG Obinutuzumab
- DRUG Ibrutinib
- OTHER CHOP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03145480
The ClinicalTrials.gov registry entry for NCT03145480 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT03145480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03145480 about?
NCT03145480 is a clinical study titled "Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients". This research study studies the combination of ibrutinib and obinutuzumab with or without the standard chemotherapy regimen of CHOP to see how well these drugs work in treating patients with a diagnosis of Richter's Transformation or Richter's Syndrome. The Bruton's Tyrosine Kinase (BTK) inhibitor, ...
What is the current status of trial NCT03145480?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-06-19. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT03145480?
The interventions under investigation include: Obinutuzumab (DRUG), Ibrutinib (DRUG), CHOP (OTHER).
Who is sponsoring clinical trial NCT03145480?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.